New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 6, 2012
16:09 EDTAMRNAmarin announces $100M non-equity financing
Amarin announced a $100M non-equity financing with an investment fund managed by Pharmakon Advisors and that Amarin is continuing its preparations to commercialize Vascepa (icosapent ethyl) capsules with the hiring of a sales force in the United States. Payments by Amarin under this hybrid debt-like instrument are expected to be made over a 3.5-year period commencing in November 2013 and to continue through early 2017. As previously announced, the initial commercial launch of Vascepa is planned for early in the first quarter of 2013. The company is hiring 250-300 specialty sales professionals for the launch of Vascepa for its initial indication, the MARINE indication, which is approved by the U.S. Food and Drug Administration. Amarin's goal is for every sales representative hired to have, at a minimum, three to five year existing relationships with the identical physician groups Amarin will be calling on and educating about Vascepa. In addition to hiring a sales force, Amarin has been focused on continued commercial preparations for Vascepa which, as previously disclosed, has included, but has not been limited to, finalizing the introduction of Vascepa to managed care plans to gain formulary access, building up inventory levels, hiring key personnel (e.g., managed care, marketing, sales infrastructure, pricing), developing direct-to-consumer advertising and speaker training and coordinating other pre-launch marketing activities. Amarin's hiring of a sales force is part of a continuing strategy to evaluate three potential paths to Vascepa commercialization: an acquisition of Amarin, a strategic collaboration, and self-commercialization, the latter of which could include third-party support.
News For AMRN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 28, 2015
16:29 EDTAMRNOn The Fly: Top stock stories for Thursday
Subscribe for More Information
14:31 EDTAMRNAmarin granted summary judgment motion in suit against FDA over Vascepa
Subscribe for More Information
13:36 EDTAMRNAmarin surges after court sides with company on Vascepa exclusivity
Shares of Amarin Pharmaceuticals are surging higher after a U.S. district court sided with the company in its challenge of the Food and Drug Administrationís determination that Amarinís new drug, Vascepa, is not entitled to a five-year period of market exclusivity under the Federal Food, Drug, and Cosmetic Act. The court granted the company's motion for summary judgment and the decision denying Amarinís claim for exclusivity was vacated. The matter was remanded to the FDA for proceedings consistent with the court's opinion. In afternoon trading, Amarin shares jumped as high as $2.80 and are now up 22.5% to $2.39.
13:29 EDTAMRNAmarin wins district court ruling on Vascepa exclusivity
Amarin shares jumped 31% following the ruling.
May 22, 2015
10:32 EDTAMRNAmarin management to meet with Oppenheimer
Meeting to be held in New York on May 27 hosted by Oppenheimer.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use